JV-Hydroxy-desferrioxamine B (5), a postulated metabolite of the microbial product desferrioxamine B (1), has been prepared by reduction of the intermediate oxime 6 with sodium cyanoborohydride. The oxime was obtained by selective oxidation of desferrioxamine B with hydrogen peroxide and a catalytic amount of sodium tungstate dihydrate. The iron complex derived from 5 enabled definite proof of the structure of one of four metabolites of desferrioxamine B found in urine samples of patients treated with this drug.
The secondary metabolite desferrioxamine B (1) was originally isolated from Streptomyces pilosus in 1960 by Bickel et al.1] The iron containing siderophore ferrioxamine B plays an important role in iron transport in microbes, plants and animals. 2) In the form of the methanesulfonate salt, the chelator desferrioxamine B (1) has been used as a drug to treat patients with transfusional iron overload or acute iron intoxication.3) Another important therapeutical application of desferrioxamine B is the removal of aluminum from patients suffering from impaired renal function and undergoing chronic haemodialysis treatment. 4'5) Recently it has been shown that the sustained administration of desferrioxamine B slowed the clinical progression of the dementia associated with Alzheimer's disease.6) Furthermore desferrioxamine B has been proposed as a promising drug for the treatment of malaria because of its inhibitory activity against plasmodia in vitro and in Wv0.7~1O) In a recent clinical trial it was shown that the administration of desferrioxamine B reduced significantly the adverse effects of reperfusion injury. 1 1>12)
Although desferrioxamine B (1) has been firmly established as a safe drug in chelation therapy, various toxic side effects have been reported, especially in patients treated with high doses.13~16) The hypothesis that the toxicity could be due to the depletion of other essential metal ions such as zinc or copper by the chelator has not been substantiated by experimental evidence.17) Since the side effcets are observed more frequently in patients with limited iron overload, it has been speculated that the toxic effects of the drug could be linked to the formation of certain metabolites.18) It is well known that ferrioxamine B, the iron complex, is quite stable towards metabolic degradation whereas the free ligand is rapidly metabolized. In view of the potentially morewidespread use of desferrioxamine B for the treatment of diseases which are not associated with chronic iron overload, such as Alzheimer's disease or malaria, it is imperative to carefully investigate the metabolism of desferrioxamine B and to evaluate the toxic potential of the metabolic products. In 1964, Keberle19) reported three metabolites in the urine of patients treated with the drug and he assigned structure (2) to the main metabolite in which the aminomethylene group of desferrioxamine B (1) is replaced by a carboxy group. The synthesis of this major metabolite (2) (2) (3) (4) (5) from the urine of treated patients (Fig. 1) . Structures of the identified metabolites (2) (3) (4) (5) were suggested based on their fast atom bombardment mass spectra. All detected metabolites (2) (3) (4) (5) are formed by a metabolic degradation at the primary amino group of desferrioxamine B. For the first time the hydroxylamine analogue of desferrioxamine B (5) was described as a metabolite of this iron chelator.
In this paper we describe the synthesis of iV-hydroxy-desferrioxamine B (5) to provide a definite proof of the proposed structure of this metabolite. In addition, the availability of reference samples of the synthetic intermediate 6 will allow investigations of the role of the oxime in the metabolic degradation pathway of desferrioxamine B.
The most widely used synthetic approach for the conversion of an amine to a hydroxylamine proceeds via the formation of a Schiff base with an aromatic aldehyde, followed by an oxidation of the intermediate imine to an oxaziridine and subsequent acid-catalyzed hydrolysis in the presence of hydroxylamine to the desired hydroxylamine derivative. The Schiff base of desferrioxamine B with p-methoxybenzaldehyde could be prepared, but the following oxidation to the corresponding oxaziridine failed due to poor solubility of the imine of desferrioxamine B in anhydrous solvents.
Considering the very low solubility of desferrioxamine B base (1) another synthetic strategy was chosen. Desferrioxamine B base was oxidized to the corresponding oxime (6) by heating a suspension of the base with 3 equivalents of hydrogen peroxide and a catalytic amount of sodium tungstate dihydrate in methanol -water, 58 : 42 (v/v) under an argon atmosphere at 50°C overnight (Scheme 1).24) The use of this solvent mixture resulted in optimal conversion. The excess of hydrogen peroxide was destroyed by stirring the reaction mixture with catalytic amounts of platinum on activated charcoal under an inert atmosphere. The oxime (6) was crystallized from water at a pH-value of 2.5 in 50%yield.
The reduction of the oxime of desferrioxamine B (6) with sodium cyanoborohydride and 2n HC1in methanol proceeded under an argon atmosphere to 7V-hydroxy-desferrioxamine B (5) (Scheme 1).25) The product was purified by preparative HPLCon reversed phase C18. The pure product could only be isolated in moderate yield (24%), presumably as a result of an autooxidative degradation reaction.
For the preparation of the iron complexes of the oxime of desferrioxamine B (7) and iV-hydroxydesferrioxamine B (8) an efficient ligand-exchange reaction was employed.26) Both the oxime of desferrioxamine B (6) and 7V-hydroxy-desferrioxamine B (5) were stirred with a slight excess of ferric acetylacetonate in a biphasic mixture consisting of ethyl acetate and water at room temperature. The water soluble ferric complex began to. form instantaneously. The extent of the reaction was monitored using analytical HPLCwhich indicated a quantitative formation of the oxime of ferrioxamine B (7) as well as of the AT-hydroxy-ferrioxamine B (8) within 2 hours. The aqueous layer was separated from the organic phase and lyophilized. By this procedure pure iron complexes were obtained without contamination by inorganic salts.
The iron complex of the synthetically prepared yV-hydroxy-desferrioxamine B was compared with the authentic metabolite isolated from urine samples of patients treated with desferroxamine B (1) by HPLC-analysis.
Identical HPLC-retention times and instability patterns could be confirmed (personal communication from Prof. Hider). In addtion both samples showed the (M +H)+-peak of 630 in the fast atom bombardment spectra. The formation of the metabolite Af-hydroxy-desferrioxamine B (5) in biological systems is not surprising: TV-hydroxylation of primary amines is a commonbioconversion reaction.27) The limited stability of Af-hydroxy-desferrioxamine B is due to autooxidation to the corresponding nitroso and nitro derivatives, a well knowndegradation process of hydroxylamines.
The structure of the recently described newmetabolite ofdesferrioxamine B has nowbeen corroborated by chemical synthesis of TV-hydroxy-desferrioxamine B (5), which was subsequently converted into the iron(III) complex. This synthetic reference material was shown to be identical to the authentic metabolite, isolated from the urine of patients, by analytical HPLCand FAB-MS.Moreover the chemical synthesis of Af-hydroxy-desferrioxamine B provides access to larger quantities of the metabolite for further pharmacokinetic studies of the metabolism of desferrioxamine B (1) and for toxicological investigations. Experimental *H NMRspectra were recorded at 360 MHz. FABmass spectra were determined on a VGZAB-HF spectrometer (VG Analytical, Manchester, UK). Melting points are uncorrected. Desferrioxamine B base was obtained from the Pharmaceutical Division of Ciba-Geigy. 30%H2O2,the peroxide test strips, ferric acetylacetonate, CH3OH(pro analysis) and CH3CN(HPLCgrade) were purchased from E. Merck.
Na2WO4 à"2H2O, NaBH3CN, platinum on activated charcoal and trifluoroacetic acid were obtained from Fluka (Buchs, Switzerland). Reaction progress and purification steps were monitored by analytical reversedphase HPLC. The stationary phase Lichrocart HPLC-cartridge (Lichrospher 100RP-18, 5 /zm, 4 x 125 mm) was purchased from E. Merck. Mobile phase A consisted of 2.2rnM KH2PO4in H2O adjusted to pH 3.0 with H3PO4 (about 0.3mM), mobile phase B was prepared by mixing 80% CH3CNwith 20% of mobile phase A. The flow rate of the mobile phase was 1.5ml/minute. The wavelength for detection was set to VOL.46 NO.2 THE JOURNAL OF ANTIBIOTICS 297 220nm. 20/xl was the injection volume for each sample. A gradient was run from 0%mobile phase B to 40% mobile phase B in 10 minutes and from 40%mobile phase B to 100% mobile phase B in 2 minutes.
Oxime of Desferrioxamine B (6) To a stirred suspension of6.0g (10.7mmol) desferrioxamine B base (1) in 70ml ofCH3OHand 50ml of H2O, 0.21g (0.64mmol) Na2WO4-2H2O in lml of H2O and 5ml (48.9mmol) of 30% H2O2 were added under an argon atmosphere. The reaction mixture was heated to 50°C and stirred overnight. The progression of the reaction was monitored by analytical HPLC(see above). The unreacted H2O2was destroyed by careful addition of 2-3 portions of 0.1 g 10% platinum on activated charcoal under a N2 atmosphere until no H2O2 could be detected in the reaction solution by peroxide test strips. This degradation of H2O2 should be done in a ventilated hood in view of the pyrophoric properties of the reaction mixture. The peroxide free reaction mixture was concentrated under vacuumto a volume of 30ml, the pH value of the solution was adjusted to 2.5 with 2n HC1 and the oxime of desferrioxamine B (6) 3420, 3310, 3150, 2930, 2860, 1650, 1620, 1565, 1460, 1425, 1395 ; FAB-MS m/z 575 (M+H)+.
Anal CalcdforC25H46N6O9(2%H2O): C 51. 21, H 8.13, N 14.33, O 26.33. Found: C 51.18, H 7.88, N 14.30, O 26.29. iV-Hydroxy-desferrioxamine B Trifluoroacetate (5) A suspension of0.5 g (0.87mmol) oxime ofdesferrioxamine B (6) and 0.055 g (0.87mmol) NaBH3CN in 50ml of CH3OHunder argon atmosphere was prepared and its pH value maintained at 3.0 by addition of ca. 2ml of 2n 50:50 (v/v) . After 35 minutes no further change of the pH value was observed and the reaction mixture was stirred for another 5hours under an argon atmosphere. The conversion of the oxime to the hydroxylamine was monitored by HPLC-analysis as described above. The solvent was removed under vacuumand the residue purified by preparative HPLCon a reversed phase C18-column (Lichroprep RP-18, 15 -25 fim) with 0.1 % aqueous trifluroacetic acid as mobile phase A and a mixture of 80%acetonitrile and 20%mobile phase A as mobile phase B. The conical column used had a diameter of 26-49mmand a length of 230mm.The flow rate of the mobile phase was 20ml/minute. A gradient was run from 5% phase B to 15% phase B in 20minutes, from 15% phase B to 28% phase B in 80 minutes and from 28%phase B to 100% phase B in 10 minutes. Detection wavelength was set to 235 nm. After purification JV-hydoxy-desferrioxamine B trifluoroacetate (5) acetate. The mixture was stirred for 2 hours. The aqueous phase was separated from the organic layer, FEB. 1993 washed with four 1 ml portions ofethyl acetate and lyophilized. Yield 90%. FAB-MSm/z 630 (M + H)+.
